Pharmacokinetics of meropenem in patients with cystic fibrosis.
The pharmacokinetics of meropenem were studied after single i.v. infusions of 15 mg meropenem/kg body weight in eight subjects with cystic fibrosis (CF) and eight healthy volunteers matched for age, sex, and weight. Significantly shorter terminal half-lives (mean, 0.74 h vs. 0.99 h) and mean residence times (mean, 1.09 h vs. 1.39 h) were noted in CF subjects. Plasma and renal clearances tended to be higher and distribution volumes smaller among the patients, but differences were not statistically significant. The results are consistent with the findings for many other beta-lactam agents used in CF patients. Assuming a MIC90 of 4 mg/l for meropenem against Pseudomonas aeruginosa, the time above the MIC was less than 3.3 h in six of the eight CF patients. This finding should be kept in mind when designing treatment regimens with meropenem in CF subjects.
Department of Infectious Diseases, Lund University Hospital, Sweden.
B A
BA
Christensson
B
B
Ljungberg
L
L
Eriksson
I
I
Nilsson-Ehle
D000328:Adult; D019540:Area Under Curve; D003550:Cystic Fibrosis / Q000150:complications* / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D000077731:Meropenem; D011552:Pseudomonas Infections / Q000150:complications* / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013845:Thienamycins / Q000493:pharmacokinetics* / Q000627:therapeutic use
D013845:Thienamycins; D000077731:Meropenem